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Adverse reactions following annual ivermectin 
treatment of onchocerciasis in Nigeria 
Wellington A. Oyibo(i) and A. F. Fagbenro-Beyioku(2) 
Objectives: This study aims to document and underscore the need to monitor adverse reactions following repeated 
ivermectin treatment under the current dispensation of the implementation of the Community-directed Treatment 
with Ivermectin (CDTI) Program. As communities are empowered to distribute ivermectin, monitoring of adverse 
reactions by health care professionals is important in achieving the onchocerciasis control objectives through mass 
ivermectin therapy. 
Methods: Eight hundred and ninety subjects from 204 randomly selected households (based on cluster of house- 
holds) were interviewed using structured questionnaires and in-depth interviews. Responses concerning the adverse 
effects of ivermectin at the first and sixth rounds were obtained using self-report and treatment records. 
Results: Of the 890 individuals, 40.67% presented with adverse reactions at the first round of treatment (TXi). This 
was reduced to 15.06% at the sixth (TX6) round of treatment. Pains in joints were more frequently reported at TX1 
and TX6,22.7% and 8.5%, respectively. 
Conclusion: The relatively mild adverse reaction rates observed at TX1 did not affect future participation in com- 
munity treatment with ivermectin, due to adequate community mobilization with health education messages. The 
current CDT1 program has a good chance of achieving the onchocerciasis control program’s objectives in Shao, 
Kwara State, Nigeria. 
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INTRODUCTION 
Treatment of onchocerciasis, a major filarial disease 
among humans and one of the leading causes of blind- 
ness, was not satisfactory until the registration of 
ivermectin in 1987. The most widely used drug before 
the advent of ivermectin was diethylcarbamizine (DEC), 
which precipitates frequent side effects and complica- 
tions in spite of its efficacy.la2 
The side effects of DEC include: pruritus, lymph 
node pain, headache, dizziness, conjunctivitis, and other 
serious complications such as hypotension, keratitis, 
chorioretinal damage, and optic neuritis.3,4 The drug’s 
rigorous dosage schedule and the adverse reactions 
were among the reasons why DEC was not recom- 
mended for mass community treatment of onchocerciasis. 
Ivermectin, on the other hand, is an effective and well- 
tolerated microfilaricidal drug that is currently em- 
ployed for large-scale treatment of onchocerciasis.5 
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Though ivermectin is well tolerated, reactions after 
treatment have been reported; these have varied with 
clinical manifestation of the disease and geographic 
region.6-9 
The rate of adverse effects following ivermectin 
treatment was reported to be as low as 13.1% by 
Chijioke and Okonkwo8 in Achi Community in south- 
eastern Nigeria. However, an adverse rate of 91.8% was 
reported at the first round of treatment in the Usambara 
Mountains of Uganda, and this was reduced to 16.6% at 
the second round of treatment.9 Reports on adverse 
effects with ivermectin vary according to the method- 
ology of evaluation, skin microfilarial density, im- 
munologic state of the individual, concurrent parasitic 
infection, and other uncertain factors.1-3,6-17 
Currently, ivermectin therapy is the major tool 
employed in controlling onchocerciasis, not only in 
Nigeria, but also in other African countries participating 
in the African Programme for Onchocerciasis Control 
(APOC). The frequency and severity of adverse 
reactions following annual ivermectin treatment are 
crucial to onchocerciasis control efforts, especially with 
the empowerment of endemic communities to under- 
take self-treatment. Thus, the adverse responses follow- 
ing community treatment of onchocerciasis in the 
APOC’s strategy of Community-directed Treatment 
with Ivermectin (CDTI) need to be frequently evaluated 
to prevent discontinuation of treatment due to adverse 
reactions. Insufficient data exist on adverse reactions 
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following annual ivermectin treatment in Nigeria, which 
is one of the most affected countries in the world. This 
study reports the response to ivermectin treatment in 
Shao, Moro Local Government Area of Kwara State, 
Nigeria, where onchocerciasis endemicity, in most cases, 
is at the meso- and hyper-endemic levels. 
MATERIALS AND METHODS 
Study area/population 
Shao is a semi-urban community located north of Ilorin, 
the administrative capital of Kwara State, Nigeria 
(latitude 08”, 35’, 40” and longitude 04”, 33’, 23”). It has 
an estimated population of 4435 people, living in 353 
households in eight administrative divisions. The studied 
population mostly comprises farmers, civil servants, 
artisans, traders and fishermen who received ivermectin 
at the inception of its distribution in 1990. 
Mass ivermectin distribution 
Mass ivermectin distribution started in 1990, using the 
clinic-based approach in the first round of ivermectin 
treatment (TXr) at basic health clinics. Subsequent 
ivermectin distribution, from 1991, was based on a 
house-to-house approach, using community-based distri- 
butors (CBDs). At the time of this study, the com- 
mencement of the seventh round of annual ivermectin 
was being awaited. Ivermectin (150 pg/kg body weight) 
was administered to each subject after weighing. 
Essentially, subjects weighing less than 15 kg, 
children under 5 years of age, severely ill persons, 
pregnant/lactating women and the aged were excluded 
from treatment. Those who weighed 25-44 kg received 
one tablet, those who weighed 45-64 kg received 1 tablet, 
and those who weighed ~65 kg received two tablets. 
Sampling method procedure 
Eight hundred and ninety subjects from 204 randomly 
selected households (based on cluster of households) 
were interviewed using structured questionnaires and 
in-depth interviews with key informants: CBDs, school 
teachers, nurses, and primary health care workers. A 
household in this study was defined as all people sleep- 
ing in the same housing unit.‘O The serially numbered 
structured questionnaires were personally administered, 
and responses were entered into a PC using the EPI 
INFO statistical package, version 6.0. 
For easy recall of post-treatment experience, only 
questions on the first year of treatment and the last 
round of treatment were asked. In addition, responses 
were matched with records of annual treatment. This 
took care of recall bias in obtaining information on 
adverse reactions. Of the responses, 98% matched with 
annual treatment records. 
RESULTS 
Eight hundred and ninety subjects from 204 randomly 
selected households within the eight divisions in Shao 
were studied. The mean age of the subjects (years)&SD 
was 36.15k15.47 (range, 12-69 years). Responses from 
the subjects using self-report matched with treatment 
records kept by the CBDs. 
Of the 890 individuals, 362 (40.7%) presented with 
adverse reactions at TXr. This number was reduced 
to 134 (15.1%) at TX6. The reduction was significant 
(PcO.05; x2=48.89; P-value=9.49; df=4). Though pains 
in joints occurred more in TX1 (22.7%) than in TX6 
(8.5%), none of the subjects reported with headache at 
TX6 (Table 1). 
The numbers of those presenting with fever (12.1%) 
and pains in joints (22.7%) were reduced at TX6 by 
77.7% and 62.5%, respectively. However, the number 
of those presenting with dizziness at TX1 increased at 
TX6. Generally, only 25.2% of the 40.7% with adverse 
reactions reported to medical personnel at any time. The 
15.5% who did not report to medical personnel had 
symptomatic reactions that subsided without medication 
as they went about their work. 
Those who reported to medical personnel had mild 
adverse reactions without functional disability. The 
majority of these subjects (20.2% of the 40.7% who 
reported adverse reactions) received ameliorative treat- 
ment (analgesics and antihistamines), but the remaining 
subjects (5%), who included those who were dizzy, did 
not receive treatment, as they only reported their 
experience and were told what to do should they have 
similar reactions, and reassured of their safety after their 
blood pressure was taken. The adverse reactions occur- 
ring at TX6 were also mild and did not necessitate a visit 
to health personnel, as the respondents had already 
been educated concerning adverse reactions following 
annual ivermectin treatment. 
DISCUSSION 
The importance of evaluating adverse reactions following 
repeated treatment of onchocerciasis with ivermectin 
under the current dispensation of CDT1 cannot be 
overemphasized. This importance is reinforced by 
Table 1. Rate of adverse reactions to ivermectin at the first 
(TXI) and sixth (TXS) rounds of treatment in Shao, Kwara State, 
Nigeria 
Adverse reactions TX7 TXS 
with ivermectin No. (%) No. (“?A) 
Pains in joints 202 (22.7) 76 (8.5) 
Headache 30 (3.4) 
Itching 18 (2.0) 2: (2.9) 
Fever 108 (12.1) 24 (2.7) 
Dizziness 4 (0.4) 8 (0.9) 
No reaction 528 (59.3) 756 (84.9) 
Subjects examined=890. 
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the regional and clinical variations that have been 
reported.7J1 
The figure of 40.7% for the reporting of adverse 
reactions to ivermectin at TX1 in this study was high 
compared with the 1.3% recorded in Liberia,lO 9% in 
the OCP Area,6 13.1% in eastern Nigeria,* 14% in 
Central Togo, l2 21.4% in Sudani 29.5% in Guatamala,14 
and 32% in Sierra Leone.7 However, higher adverse 
reaction rates with ivermectin have also been docu- 
mented in Guatemala (60%),ls Malawi (62.9%),11 and 
Tanzania (91.8%).9 The relatively high adverse reaction 
rate of 40.7% at TX1 observed in this study was pro- 
bably due to individuals with trivial reactions (15.4% of 
the 40.7%) who did not report to medical personnel at 
the time of treatment but now had the opportunity of 
recounting their experiences using our retrospective 
approach. The frequencies of adverse reaction reported 
might differ from one study to another, based on the 
approach to evaluation. lo>15 Zea-Flores et all5 reported 
that the high frequency of adverse reactions in their 
study might be attributable to their active surveillance 
system, where patients were asked whether they had any 
health problems after their last visit. In our retrospective 
study, the subjects were skilfully questioned on their 
post-treatment experiences in the presence of key 
informants, e.g. the CBDs. Responses were then matched 
with treatment records, which revealed that only 25.0% 
actually reported to medical personnel. It is worth 
recognizing here that annual ivermectin treatment, com- 
pared to other control programs for onchocerciasis 
control, is popular with the people, who remember the 
events following annual treatment. In addition, the de- 
worming effect of the drug and other perceived benefits 
make ivermectin an acceptable drug. 
The pathogenesis of adverse reactions to ivermectin 
is uncertain, but is most likely an acceleration by treat- 
ment of events normally associated with destruction of 
microfilariae by the host.ll Though post-treatment 
ivermectin reactions have been related to skin micro- 
filarial load,6*8,11 there are also reports from Sudan, for 
example, which show that reactions could be exacer- 
bated in patients with severe asymmetric reactive 
onchodermatitis (sowda)13 (probably due to immune- 
dependent mechanisms, e.g. hyperreactive immunologic 
stimulation) and concurrent infection with Loa Zoa.17 
There was no relationship between ivermectin concen- 
trations and the grade of adverse reactions in an 
investigation by Njoo et all8 on whether serum ivermectin 
levels correlated with adverse reactions and whether 
patients with mild or no reactions and high microfilarial 
densities had distinctly lower ivermectin levels than 
those with low microfilarial densities. Nevertheless, 
microfilarial density may be a risk factor for the 
development of a reaction, but the degree of severity 
could be a feature of the clinicopathologic manifesta- 
tions of infection with Onchocerca volvulus.13 
The 63% reduction in adverse reactions follow- 
ing ivermectin treatment reported at TX1 compared 
with that at TX6 in this study is remarkable. It agrees 
with reports that initial adverse reactions referred to 
as Mazzotti reactions are related to massive killing of 
microfilariae and subside following subsequent treat- 
ments.6,7J1 Collins et all4 reported a reduction in post- 
treatment reactions with ivermectin from 29.5% at TX1 
to 9.9%, 10.3%, 8.2% and 7.1% for the second to fifth 
treatments respectively (a reduction of 75.9% between 
TX1 and TXS). In addition, Mwetta and Hills9 recorded 
a drop in adverse reactions from 91.8% at TX1 to 16.6% 
at TX2. 
That most adverse effects of ivermectin resolved 
spontaneously or were relieved with analgesics and anti- 
histamines provided by the community health worker 
indicated that ivermectin is safe and well tolerated in 
this community. Though pains in joints followed by fever 
occurred more at TX1 in this study, pruritus followed by 
fever was reported in eastern Nigeria.8 Whitworth et ali6 
listed itching and/or rash and muscle and/or joint pains 
as the first and second most common presentations 
respectively. De Sole et a1,6 however, recorded more 
instances of pain, while Zea-Flores et all5 reported fever 
as the second most common adverse ivermectin 
reaction. When the adverse reactions reported in this 
study are compared to those in a previous study in 
Malawi,ll ivermectin can be said to be well tolerated, 
with less severe reactions. In Malawi, the adverse 
reactions reported at the first year of treatment 
included: body pains (33.7%), joint pains (21.0%) 
backache (24.7%), headache (37.6%), abdominal pain 
(14.5%), eye pain (3.7%), swollen face (12.9%), itching 
(34.3%),rash (9%), dizziness (8.7%),fever (5.3%),chills 
(3.7%) and palpitations (1.8%). It was also reported 
from Malawi that edema, in 62.3% of the instances, 
occurred within the first 24 h, with edema of the face 
appearing more quickly, while in some persons it did not 
appear until 7-14 days after treatment. The reason for 
the variation in the time to the occurrence of adverse 
reactions from one region to another is not clear, as 
none of the subjects in this study had delayed reactions. 
All of the adverse reactions recorded in this study 
occurred within 24 h of treatment. 
Ivermectin is well accepted in Shao, because of 
adequate mobilization by health officials. This may be 
partly due to the fact that this community was among 
the communities used in developing a model com- 
munity-based control program with ivermectin. Adequate 
community mobilization with health education materials 
is very important, especially before and within the first 
few years of ivermectin treatment. When the people are 
informed of the likely adverse effects of ivermectin, 
adverse experiences will not dissuade them from 
receiving the drug at the next round of annual distri- 
bution. Indeed, the success of the CMDTI hinges on 
continued participation in the ivermectin distribution 
exercise in order to achieve the objectives of the control 
program. This makes continued monitoring of adverse 
reaction rates imperative, so that measures can be put 
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into place to mobilize the community for future treat- 
ment. It is important to note that the immediate in- 
stitution of health education messages promoted the 
further use of ivermectin following a high incidence of 
facial edema at the first round of treatment in Malawi.ll 
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